

FIGURE 1

2/19




FIGURE 2a

3/19




FIGURE 2b




FIGURE 3

HPLC of isoliquirtigenin




FIGURE 4

6/19

UV spectrum of Isoliquiritigenin




FIGURE 5

I-3-4





FIGURE 6a

8/19



1-3-4 C13-2 01=4s scan 10000

Pulse Sequence: zgpg1

FIGURE 6b

9/19




FIGURE 7

Cell viability (MTT) curves for Wogonin treatment of LNCaP and DU145




FIGURE 8

Cell viability (MTT) curves for isoliquiritigenin treatment of LNCaP, DU145 and MCF-7




FIGURE 9

Cell cycle distribution of LNCaP cells of 48h treatment by Wogonin




FIGURE 10

Effects of Isoliquirtigenin and Wogonin on cell cycle of LNCaP




FIGURE 11

Effects of Isoliquirtigenin and Wogonin on cell cycle of DU145




FIGURE 12

ERE-Luc Reporter Activation in 293 Cells
Transfected with hERalpha




FIGURE 13

ERE-Luc Reporter Activation in 293 Cells
Transfected with hERbeta




FIGURE 14


Inhibitory activity of isoliquiritigenin on COX-2

Figure 15




Figure 16




Figure 17